Winning a ruling in their favor Monday, AstraZeneca and its rare disease unit Alexion have successfully sidestepped U.S. antitrust allegations linked to aging rare disease drug Soliris.
U.S. District Judge Brian Murphy sided with Alexion, granting the company's motion for judgment on the pleadings in a lawsuit brought before a Massachusetts federal court last year by nonprofit health plan EmblemHealth, a purchaser of the C5 inhibitor that argued it had overpaid as a result of Alexion's purported actions.
Shortly after Soliris began to face biosimilar competition in the U.S., EmblemHealth alleged in a lawsuit that Alexion had extended the drug's exclusivity runway with “fraudulent” additional patents and asserted those protections against would-be competitors to stall the arrival of lower-cost Soliris biosimilars until 2025.
Though still a blockbuster medicine listed (PDF) alongside other “revenue drivers” in AstraZeneca's 2025 financial results, the British Big Pharma has been acutely aware that Soliris' reign is on the decline.
For several years now, the company has been working to convert patients on Soliris, approved for conditions including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis and neuromyelitis optica spectrum disorder, to its successor biologic Ultomiris.
Alexion secured its original patent for Soliris in 2002, five years before the drug's FDA approval. That patent was initially set to expire in 2019 before being extended to 2021, while additional patents obtained in 2017 and 2020 provided protections stretching into 2027.
As biosimilar competitors sought to enter the market, Alexion sued Samsung Bioepis for patent infringement in January 2024. The companies settled that August, with Samsung agreeing to drop its challenges to Alexion's patents and delay the launch of its Soliris biosimilar until April 2025.
That lawsuit became a central part of EmblemHealth's antitrust case. The insurer argued that Alexion had used its patents and litigation against Samsung to improperly delay lower-cost competition, forcing U.S. purchasers of Soliris to overpay by an estimated $2 billion.
But Murphy rejected EmblemHealth's argument that the Samsung litigation was a “sham,” finding that the settlement's favorable terms for Alexion undermined the claim that its lawsuit was baseless. The judge ruled that Alexion was therefore protected from the remaining antitrust claims under a legal doctrine that generally shields companies from antitrust liability for enforcing their intellectual property rights. Murphy separately found that EmblemHealth lacked standing to pursue federal antitrust claims and claims under state laws applying similar standards.
To date, two biosimilars to Soliris have reached the U.S. market: Amgen's Bkemv and Teva and Samsung Bioepis' Epysqli.
Soliris, for its part, racked up sales of more than $1.8 billion in 2025, down 28% at constant exchange rates compared with 2024. Ultomiris, meanwhile, posted a 19% gain at constant exchange rates to reach annual revenue of $4.7 billion.
As Ultomiris continues to pick up the slack from its predecessor medicine, AstraZeneca and Alexion have recently made new strides in the rare disease field, specifically in the realm of generalized myasthenia gravis (gMG).
AZ scored approvals in both the U.S. and European Union this week for C5 inhibitor gefurulimab under the brand name Klygefa, a new autoinjector treatment for certain adults with gMG that can be administered by patients or caregivers at home.
Soliris and Ultomiris, on the other hand, are given as intravenous infusions.